100427-26-7

Basic information

• Product Name: Lercanidipine
• Synonyms: LERCANIDIPINE;methyl [2-(3,3-diphenylpropyl-methyl-amino)-1,1-dimethyl-ethyl] 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate;1,4-DIHYDRO-2,6-DIMETHYL-4-(3-NITTROPHENYL)-3,5-PYRIDINEDICARBOXYLIC ACID 2-[(3,3-DIPHENYLPROPYL)METHYLAMINO]-1,1-DIMETHYLETHYL METHYL ESTER;LercanidipineC36H41N306;LERCANIDIPINE(FORR&DONLY);1,4-Dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-[2-[(3,3-diphenylpropyl)methylamino]-1,1-dimethylethyl]5-methyl ester;2,6-Dimethyl-4-(3-nitrophenyl)-1,4-dihydro-3,5-pyridinedicarboxylic acid 3-methyl 5-[1,1-dimethyl-2-[methyl(3,3-diphenylpropyl)amino]ethyl] ester;Masnidipine
• CAS NO: 100427-26-7
• Molecular Formula: C₃₆H₄₁N₃O₆
• Molecular Weight: 611.73
• EINECS: 1806241-263-5
• Product Categories: Inhibitors;inhibitor
• Mol File: 100427-26-7.mol

Chemical Properties

• Melting Point: 118-120°C
• Boiling Point: 712.5 °C at 760 mmHg
• Flash Point: 384.7 °C
• Appearance: white powder
• Density: 1.177 g/cm³
• Vapor Pressure: 3.77E-20mmHg at 25°C
• Refractive Index: 1.579
• CAS DataBase Reference: Lercanidipine(CAS DataBase Reference)
• NIST Chemistry Reference: Lercanidipine(100427-26-7)
• EPA Substance Registry System: Lercanidipine(100427-26-7)

Safety Data

• Hazardous Substances Data: 100427-26-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Lercanidipine is used as an antihypertensive compound for the treatment of hypertension. It functions as a calcium channel blocker, helping to relax blood vessel walls and thus lowering blood pressure. Its tissue selectivity and lack of negative inotropic effects make it a preferred choice for patients with hypertension.
Used in Cardiovascular Applications:
Lercanidipine is used as a cardiovascular agent to improve cardiac contractility without causing negative inotropic effects. Its increased cardiac contractility index, compared to other dihydropyridine calcium channel blockers, makes it a valuable option for patients with cardiovascular conditions.
Brand Names:
Cardiovasc (Recor dati, Italy)
Carmen (Recordati, Italy)
Corifeo (Recordati, Italy)
Lercadip (Recordati, Italy)
Lercan (Recordati, Italy)
Lercapin (Recordati, Italy)
Lercaton (Recordati, Italy)
Lerkamen (Recordati, Italy)
Lerzam (Recordati, Italy)
Renovia (Recordati, Italy)
Vasodip (Recordati, Italy)
Zandip (Recordati, Italy)
Zanicor (Recordati, Italy)

Originator

Recordati (Italy)

InChI:InChI=1/C36H41N3O6/c1-24-31(34(40)44-6)33(28-18-13-19-29(22-28)39(42)43)32(25(2)37-24)35(41)45-36(3,4)23-38(5)21-20-30(26-14-9-7-10-15-26)27-16-11-8-12-17-27/h7-19,22,30,33,37H,20-21,23H2,1-6H3

Upstream product

• 74936-72-4 5-methoxycarbonyl-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylic acid 
• 88712-56-5 1,4-dihydro-2,6-dimethyl-3-methoxycarbonyl-4-(3-nitrophenyl)-pyridine-5-carboxylic acid chloride 
• 132866-11-6 lercanidipine hydrochloride 
• 100427-53-0 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl α-acetyl-3-nitrocinnamate 
• 21731-17-9 methyl 3-aminocrotonate 
• 100427-51-8 1,1,N-trimethyl-N-(3,3-diphenylpropy)-2-aminoethyl acetoacetate 
• 100442-33-9 2,N-dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol 
• 28075-29-8 N-methyl-3,3-diphenylpropylamine 
• 210579-45-6 2-[1-(3-Nitro-phenyl)-meth-(E)-ylidene]-3-oxo-butyric acid 2-[(3,3-diphenyl-propyl)-methyl-amino]-1,1-dimethyl-ethyl ester 

Downstream Products

• 877372-46-8 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate besylate 
• 1220908-17-7 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate napadisylate 
• 877372-45-7 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate saccharinate 
• 877372-42-4 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate cinnamate 
• 877372-43-5 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate salicylate 
• 877372-41-3 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate L-lactate 
• 877372-48-0 methyl 1,1,N-trimethyl-N-(3,3-diphenylpropyl)-2-aminoethyl 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate maleate 
• 132866-11-6 lercanidipine hydrochloride 

Related news

Evaluation of the Efficacy and Safety of the Lercanidipine (cas 100427-26-7)/Valsartan Combination in Korean Patients With Essential Hypertension Not Adequately Controlled With Lercanidipine (cas 100427-26-7) Monotherapy: A Randomized, Multicenter, Parallel Design, Phase III Clinical Trial07/31/2019

PurposeThe objective of this study was to evaluate the efficacy and safety of the lercanidipine/valsartan combination compared with lercanidipine monotherapy in patients with hypertension.detailed

Neuroprotective effect of Lercanidipine (cas 100427-26-7) in middle cerebral artery occlusion model of stroke in rats07/29/2019

Oxidative stress, inflammation and apoptotic neuronal cell death are cardinal mechanisms involved in the cascade of acute ischemic stroke. Lercanidipine apart from calcium channel blocking activity possesses anti-oxidant, anti-inflammatory and anti-apoptotic properties. In the present study, we ...detailed

Relevant articles and documents

THERAPY FOR COMPLICATIONS OF DIABETES

A method for enhancing glycemic control and/or insulin sensitivity in a human subject having diabetic nephropathy and/or metabolic syndrome comprises administering to the subject a selective endothelin A (ETA) receptor antagonist in a glycemic control and/or insulin sensitivity enhancing effective amount. A method for treating a complex of comorbidities in an elderly diabetic human subject comprises administering to the subject a selective ETA receptor antagonist in combination or as adjunctive therapy with at least one additional agent that is (i) other than a selective ETA receptor antagonist and (ii) effective in treatment of diabetes and/or at least one of said comorbidities other than hypertension. A therapeutic combination useful in such a method comprises a selective ETA receptor antagonist and at least one antidiabetic, anti-obesity or antidyslipidemic agent other than a selective ETA receptor antagonist.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Method for treating resistant hypertension

A method is provided for lowering blood pressure in a patient having clinically diagnosed resistant hypertension. The method comprises administering darusentan to the patient adjunctively with a baseline antihypertensive regimen that comprises administration of at least one diuretic and at least two antihypertensive drugs selected from at least two of (a) ACE inhibitors and angiotensin II receptor blockers, (b) beta-adrenergic receptor blockers and (c) calcium channel blockers. The darusentan is orally administered at a dose and frequency effective, in combination with the baseline regimen, to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures.

A NOVEL PROCESS FOR THE PREPARATION OF LERCANIDIPINE

The invention provides a novel process for the preparation of lercanidipine or a pharmaceutical acceptable salt using novel intermediates. Thus, 2,N-dimethyl-N-(3,3-diphenylpropyl)-1-amino-2-propanol is reacted with trimethylsilyl chloride in presence of

Solid lercanidipine free base

The invention provides substantially pure lercanidipine free base, having a purity of at least 95%, preferably at least 97%, more preferably at least 99%, and still more preferably at least 99.5%. The lercanidipine free base of the present invention is fo

Asymmetric N-(3,3-diphenylpropyl)aminoalkyl esters of 4-aryl-2,6- dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acids with antihypertensive activity

A series of asymmetric 4-aryl-1,4-dihydropyridine-3,5-dicarboxylates characterized by the presence of a 3,3-diphenylpropylamino moiety in one of the ester groups were synthesized. They exhibited remarkable antihypertensive activity in spontaneously hypertensive rats as well as affinity for the 1,4- dihydropyridines binding site labelled by 3H-nitrendipine in the calcium channel. Introduction of this bulky and lipophilic amine confers to the whole series an elevated level of antihypertensive activity and a long duration of action, a structure-dependent modulation of the activity being found only in the subset characterized by the presence of a branched propylene bridge between the ester and the amino groups. The presence of the amino group is essential for oral activity. Out of this series, compound 9u (Rec 15/2375- lercanidipine) was selected for clinical development and obtained marketing authorization as an antihypertensive in several countries.